Literature DB >> 11496956

Oral delivery of biologically active parathyroid hormone.

A Leone-Bay1, M Sato, D Paton, A H Hunt, D Sarubbi, M Carozza, J Chou, J McDonough, R A Baughman.   

Abstract

PURPOSE: Parathyroid hormone (PTH), the only drug known to stimulate bone formation. is a peptide therapeutic indicated in the treatment of osteoporosis. Unfortunately, PTH is only effective when dosed by injection because it has no oral bioavailability. Herein we report the oral absorption of PTH in rats and monkeys facilitated by the novel delivery agent, N-[8-(2-hydroxy-4-methoxy)bensoyl]amino caprylic acid (4-MOAC).
METHODS: 4-MOAC was selected from a group of 100 delivery agents based on in vitro chromotography studies and in vivo screening studies in rats. The PTH/4-MOAC combination was then tested in monkeys. The interaction of 4-MOAC and PTH was evaluated by nuclear magnetic resonance (NMR) spectroscopy.
RESULTS: Monkeys were administered an aqueous solution containing 4-MOAC and PTH and mean peak serum PTH concentrations of about 3000 pg/mL were obtained. The relative bioavailability of oral PTH was 2.1% relative to subcutaneous administration. The biological activity of the orally-delivered PTH was further evaluated in a rat model of osteoporosis. These studies showed that the bone formed following oral PTH/4-MOAC administration was comparable to that formed following PTH injections. The 4-MOAC mediated absorption of PTH is hypothesized to be the result of a noncovalent interaction between 4-MOAC and PTH. The preliminary evaluation of this interaction by NMR is described.
CONCLUSIONS: 4-MOAC facilitates the absorption of PTH following oral administration to both rats and monkeys. The orally-absorbed PTH is biologically active as demonstrated in a rat model of osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496956     DOI: 10.1023/a:1010936227570

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  19 in total

Review 1.  NMR screening in drug discovery.

Authors:  J M Moore
Journal:  Curr Opin Biotechnol       Date:  1999-02       Impact factor: 9.740

2.  The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats.

Authors:  H Dobnig; R T Turner
Journal:  Endocrinology       Date:  1997-11       Impact factor: 4.736

3.  Folding proteins into membranes.

Authors:  C M Deber; N K Goto
Journal:  Nat Struct Biol       Date:  1996-10

4.  Oral delivery of heparin in combination with sodium N-[8-(2-hydroxybenzoyl)amino]caprylate: pharmacological considerations.

Authors:  T M Rivera; A Leone-Bay; D R Paton; H R Leipold; R A Baughman
Journal:  Pharm Res       Date:  1997-12       Impact factor: 4.200

5.  Sodium deoxycholate promotes the absorption of heparin administered orally, probably by acting on gastrointestinal mucosa, in rats.

Authors:  S Guarini; W Ferrari
Journal:  Experientia       Date:  1985-03-15

6.  Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats.

Authors:  M Sato; J Kim; L L Short; C W Slemenda; H U Bryant
Journal:  J Pharmacol Exp Ther       Date:  1995-03       Impact factor: 4.030

7.  Acylated non-alpha-amino acids as novel agents for the oral delivery of heparin sodium, USP.

Authors:  A Leone-Bay; D R Paton; B Variano; H Leipold; T Rivera; J Miura-Fraboni; R A Baughman; N Santiago
Journal:  J Control Release       Date:  1998-01-02       Impact factor: 9.776

Review 8.  The ovariectomized rat model of postmenopausal bone loss.

Authors:  D N Kalu
Journal:  Bone Miner       Date:  1991-12

9.  Comparative x-ray densitometry of bones from ovariectomized rats.

Authors:  M Sato
Journal:  Bone       Date:  1995-10       Impact factor: 4.398

10.  Structure of human parathyroid hormone 1-37 in solution.

Authors:  U C Marx; S Austermann; P Bayer; K Adermann; A Ejchart; H Sticht; S Walter; F X Schmid; R Jaenicke; W G Forssmann
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

View more
  16 in total

Review 1.  Gut hormones: the future of obesity treatment?

Authors:  Anne K McGavigan; Kevin G Murphy
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

2.  Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array.

Authors:  Elizabeth R Proos; James H Prescott; Mark A Staples
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

Review 3.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  A randomly coiled, high-molecular-weight polypeptide exhibits increased paracellular diffusion in vitro and in situ relative to the highly ordered alpha-helix conformer.

Authors:  Nazila Salamat-Miller; Montakarn Chittchang; Ashim K Mitra; Thomas P Johnston
Journal:  Pharm Res       Date:  2005-02       Impact factor: 4.200

5.  Oral absorption enhancement of cromolyn sodium through noncovalent complexation.

Authors:  Xuan Ding; Parshuram Rath; Robert Angelo; Thomas Stringfellow; Elizabeth Flanders; Steven Dinh; Isabel Gomez-Orellana; Joseph R Robinson
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

Review 6.  Approaches for enhancing oral bioavailability of peptides and proteins.

Authors:  Jwala Renukuntla; Aswani Dutt Vadlapudi; Ashaben Patel; Sai H S Boddu; Ashim K Mitra
Journal:  Int J Pharm       Date:  2013-02-18       Impact factor: 5.875

7.  Development of Potent, Protease-Resistant Agonists of the Parathyroid Hormone Receptor with Broad β Residue Distribution.

Authors:  Ross W Cheloha; Bingming Chen; Niyanta N Kumar; Tomoyuki Watanabe; Robert G Thorne; Lingjun Li; Thomas J Gardella; Samuel H Gellman
Journal:  J Med Chem       Date:  2017-10-24       Impact factor: 7.446

Review 8.  Combination/sequential therapies for anabolic and antiresorptive skeletal agents for osteoporosis.

Authors:  John P Bilezikian; Mishaela R Rubin
Journal:  Curr Osteoporos Rep       Date:  2006-03       Impact factor: 5.096

9.  Diphtheria Toxin- and GFP-Based Mouse Models of Acquired Hypoparathyroidism and Treatment With a Long-Acting Parathyroid Hormone Analog.

Authors:  Ruiye Bi; Yi Fan; Kelly Lauter; Jing Hu; Tomoyuki Watanabe; Jim Cradock; Quan Yuan; Thomas Gardella; Michael Mannstadt
Journal:  J Bone Miner Res       Date:  2016-01-20       Impact factor: 6.741

10.  Protein and Peptide drug delivery: oral approaches.

Authors:  Jessy Shaji; V Patole
Journal:  Indian J Pharm Sci       Date:  2008 May-Jun       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.